Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liver Corelle Tablet, also known as Ganxin Tablet (肝心片), is a traditional Chinese medicine (TCM) product developed and manufactured by Shanxi Buchang Pharmaceutical. It is primarily indicated for the treatment of liver diseases, including chronic hepatitis and early-stage liver cirrhosis. The formulation is designed to provide hepatoprotective effects, reduce elevated serum transaminase levels (such as ALT and AST), and inhibit liver fibrosis. As a Chinese patent medicine, it typically consists of a combination of herbal extracts, including *Salvia miltiorrhiza* and *Schisandra chinensis*, which are known for their anti-inflammatory and liver-supporting properties. It is approved for marketing in China and is administered orally in tablet form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ganxin tablet.